Minnesota HF5147 modifies income and corporate franchise tax provisions by adding pharmaceutical marketing expenses as an addition.

Minnesota HF5147 amends tax provisions by adding direct-to-consumer pharmaceutical marketing expenses as an addition. This change applies to expenses deducted under section 162 of the Internal Revenue Code for marketing activities directed toward consumers in the United States, including television, radio, print, digital, and social media advertising. The bill defines "direct-to-consumer pharmaceutical marketing" and "pharmaceutical manufacturer" for clarity. The amendment takes effect for taxable years beginning after December 31, 2026.

Minnesota HF5147 modifies income and corporate franchise tax provisions by adding pharmaceutical marketing expenses as an addition.

Minnesota HF5147 amends tax provisions by adding direct-to-consumer pharmaceutical marketing expenses as an addition. This change applies to expenses deducted under section 162 of the Internal Revenue Code for marketing activities directed toward consumers in the United States, including television, radio, print, digital, and social media advertising. The bill defines "direct-to-consumer pharmaceutical marketing" and "pharmaceutical manufacturer" for clarity. The amendment takes effect for taxable years beginning after December 31, 2026.